Piperacillin/tazobactum

Drug Profile

Piperacillin/tazobactum

Alternative Names: YH-1177; YH-1177D

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Yuhan
  • Class
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Otitis media

Most Recent Events

  • 01 Jul 2016 Yuhan Corporation plans a phase I/II trial for Otitis media in South Korea (NCT02817347)
  • 01 Jun 2016 Phase-I/II clinical trials in Otitis media in South Korea (Otic)
  • 15 Dec 2014 Preclinical trials in Otitis media in South Korea (Otic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top